UroGen Pharma Ltd. NASDAQ:URGN

UroGen Pharma Ltd. stock price today

$18.95
+8.19
+76.12%
Financial Health
0
1
2
3
4
5
6
7
8
9

UroGen Pharma Ltd. stock price monthly change

-36.44%
month

UroGen Pharma Ltd. stock price quarterly change

-36.44%
quarter

UroGen Pharma Ltd. stock price yearly change

-25.28%
year

UroGen Pharma Ltd. key metrics

Market Cap
437.18M
Enterprise value
256.60M
P/E
-1.92
EV/Sales
6.74
EV/EBITDA
-2.53
Price/Sales
5.55
Price/Book
-3.34
PEG ratio
-0.12
EPS
-3.40
Revenue
84.30M
EBITDA
-66.29M
Income
-104.31M
Revenue Q/Q
9.24%
Revenue Y/Y
24.00%
Profit margin
-287.38%
Oper. margin
-206.73%
Gross margin
81.66%
EBIT margin
-206.73%
EBITDA margin
-78.64%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

UroGen Pharma Ltd. stock price history

UroGen Pharma Ltd. stock forecast

UroGen Pharma Ltd. financial statements

Average Price Target
Last Year

$25

Potential upside: 31.92%

Based on estimate of 1 analysts
  • Analysts Price target

  • Financials & Ratios estimates

UroGen Pharma Ltd. (NASDAQ:URGN): Profit margin
Jun 2023 21.13M -24.13M -114.18%
Sep 2023 20.85M -21.87M -104.93%
Dec 2023 23.53M -26.01M -110.57%
Mar 2024 18.78M -32.28M -171.91%
UroGen Pharma Ltd. (NASDAQ:URGN): Debt to assets
Jun 2023 95361000 233.79M 245.17%
Sep 2023 193633000 235.62M 121.69%
Dec 2023 178311000 243.52M 136.57%
Mar 2024 200574000 240.70M 120.01%
UroGen Pharma Ltd. (NASDAQ:URGN): Cash Flow
Jun 2023 -20.27M 3.72M 143K
Sep 2023 -17.29M 401K 116.07M
Dec 2023 -13.05M -10.98M 40K
Mar 2024 -31.73M 13.51M 54.65M

UroGen Pharma Ltd. alternative data

UroGen Pharma Ltd. (NASDAQ:URGN): Employee count
Aug 2023 194
Sep 2023 193
Oct 2023 193
Nov 2023 193
Dec 2023 192
Jan 2024 192
Feb 2024 192
Mar 2024 198
Apr 2024 198
May 2024 198
Jun 2024 204
Jul 2024 204

UroGen Pharma Ltd. other data

63.63% -2.17%
of URGN is owned by hedge funds
14.21M -505.88K
shares is hold by hedge funds

UroGen Pharma Ltd. (NASDAQ:URGN): Insider trades (number of shares)
Period Buy Sel
Aug 2023 0 3800
Jan 2024 0 8782
Feb 2024 0 8782
Mar 2024 0 12000
Jun 2024 0 5153
Transaction Date Insider Security Shares Price per share Total value Source
Option
SCHOENBERG MARK officer: Chief Me.. Ordinary Shares 10,000 N/A N/A
Sale
SCHOENBERG MARK officer: Chief Me.. Ordinary Shares 5,153 $13.08 $67,401
Option
SCHOENBERG MARK officer: Chief Me.. Restricted Stock Units 10,000 N/A N/A
Sale
SCHOENBERG MARK officer: Chief Me.. Ordinary Shares 12,000 $14.05 $168,600
Sale
SMITH JASON DREW officer: General .. Ordinary Shares 3,328 $15.78 $52,516
Sale
SMITH JASON DREW officer: General .. Ordinary Shares 3,328 $15.78 $52,516
Sale
SMITH JASON DREW officer: General .. Ordinary Shares 1,248 $15.78 $19,693
Sale
SMITH JASON DREW officer: General .. Ordinary Shares 1,248 $15.78 $19,693
Sale
SMITH JASON DREW officer: General .. Ordinary Shares 417 $15.78 $6,580
Sale
SMITH JASON DREW officer: General .. Ordinary Shares 417 $15.78 $6,580
Patent
Application
Filling date: 9 Dec 2021 Issue date: 30 Jun 2022
Application
Filling date: 31 Dec 2021 Issue date: 21 Apr 2022
Grant
Filling date: 25 Jun 2015 Issue date: 4 May 2021
Application
Filling date: 31 Aug 2020 Issue date: 24 Dec 2020
Application
Filling date: 4 Oct 2019 Issue date: 3 Sep 2020
Grant
Filling date: 11 Mar 2019 Issue date: 1 Sep 2020
Application
Filling date: 22 Jul 2019 Issue date: 16 Apr 2020
Grant
Filling date: 15 Oct 2013 Issue date: 12 Nov 2019
Friday, 6 December 2024
businesswire.com
Thursday, 5 December 2024
businesswire.com
businesswire.com
Monday, 2 December 2024
zacks.com
businesswire.com
Tuesday, 26 November 2024
businesswire.com
Wednesday, 13 November 2024
seekingalpha.com
Wednesday, 6 November 2024
seekingalpha.com
zacks.com
businesswire.com
Monday, 17 June 2024
businesswire.com
globenewswire.com
zacks.com
Thursday, 13 June 2024
businesswire.com
businesswire.com
businesswire.com
Friday, 7 June 2024
businesswire.com
Thursday, 6 June 2024
businesswire.com
Wednesday, 5 June 2024
businesswire.com
Monday, 3 June 2024
businesswire.com
Wednesday, 22 May 2024
businesswire.com
Monday, 13 May 2024
seekingalpha.com
businesswire.com
Tuesday, 7 May 2024
businesswire.com
Sunday, 5 May 2024
businesswire.com
Saturday, 4 May 2024
businesswire.com
businesswire.com
Friday, 3 May 2024
businesswire.com
Wednesday, 17 April 2024
businesswire.com
Monday, 15 April 2024
businesswire.com
  • What's the price of UroGen Pharma Ltd. stock today?

    One share of UroGen Pharma Ltd. stock can currently be purchased for approximately $18.95.

  • When is UroGen Pharma Ltd.'s next earnings date?

    Unfortunately, UroGen Pharma Ltd.'s (URGN) next earnings date is currently unknown.

  • Does UroGen Pharma Ltd. pay dividends?

    No, UroGen Pharma Ltd. does not pay dividends.

  • How much money does UroGen Pharma Ltd. make?

    UroGen Pharma Ltd. has a market capitalization of 437.18M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 28.52% to 82.71M US dollars.

  • What is UroGen Pharma Ltd.'s stock symbol?

    UroGen Pharma Ltd. is traded on the NASDAQ under the ticker symbol "URGN".

  • What is UroGen Pharma Ltd.'s primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of UroGen Pharma Ltd.?

    Shares of UroGen Pharma Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are UroGen Pharma Ltd.'s key executives?

    UroGen Pharma Ltd.'s management team includes the following people:

    • Ms. Elizabeth A. Barrett Pres, Chief Executive Officer & Director(age: 63, pay: $1,150,000)
    • Dr. Mark P. Schoenberg Chief Medical Officer(age: 67, pay: $479,940)
    • Mr. Jason Drew Smith Gen. Counsel & Chief Compliance Officer(age: 53, pay: $338,530)
    • Ms. Molly Henderson CPA, MBA Chief Financial Officer(age: 54, pay: $279,340)
  • How many employees does UroGen Pharma Ltd. have?

    As Jul 2024, UroGen Pharma Ltd. employs 204 workers, which is 3% more then previous quarter.

  • When UroGen Pharma Ltd. went public?

    UroGen Pharma Ltd. is publicly traded company for more then 8 years since IPO on 4 May 2017.

  • What is UroGen Pharma Ltd.'s official website?

    The official website for UroGen Pharma Ltd. is urogen.com.

  • Where are UroGen Pharma Ltd.'s headquarters?

    UroGen Pharma Ltd. is headquartered at 400 Alexander Park, Princeton, NJ.

  • How can i contact UroGen Pharma Ltd.?

    UroGen Pharma Ltd.'s mailing address is 400 Alexander Park, Princeton, NJ and company can be reached via phone at +64 6 768 9780.

  • What is UroGen Pharma Ltd. stock forecast & price target?

    Based on 1 Wall Street analysts` predicted price targets for UroGen Pharma Ltd. in the last 12 months, the avarage price target is $25. The average price target represents a 31.92% change from the last price of $18.95.

UroGen Pharma Ltd. company profile:

UroGen Pharma Ltd.

urogen.com
Exchange:

NASDAQ

Full time employees:

217

Industry:

Biotechnology

Sector:

Healthcare

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

400 Alexander Park
Princeton, NJ 08540

CIK: 0001668243
ISIN: IL0011407140
CUSIP: M96088105